Why Is GENTEX CORP (GNTX) Stock Down Today?

Gentex Corporation (GNTX) stock fell 6.13% to $22.34 in early trading on July 24, 2026, following the release of its second-quarter financial results. The stock opened with a 0.8% gap up but quickly reversed to a session low of $22.20. The decline reflects mixed earnings performance, with non-GAAP earnings per share of $0.58 beating estimates but revenue of $651.3 million falling short by $18.25 million. The company attributed the revenue miss to weaker auto sales in Europe and Asia, partially offset by stronger performance in North America.

What Happened

Gentex reported second-quarter 2026 results on July 24, with the SEC filing an 8-K disclosing the results of operations and financial condition. The company’s non-GAAP earnings of $0.58 per share exceeded the $0.50 estimate, representing a 6.4% year-over-year increase. However, revenue of $651.3 million missed the $669.545 million estimate, driven by softness in international markets. Gentex affirmed its full-year 2026 sales guidance of $2.650 billion to $2.750 billion, slightly below the $2.692 billion estimate. The company also reaffirmed its 2027 guidance of $2.8 billion to $2.9 billion. The stock’s sharp intraday decline suggests investors were more focused on the revenue shortfall than the earnings beat.

What The Data Shows

The stock opened at $23.99 and fell to a low of $22.20, trading at the bottom of its 52-week range of $20.48 to $29.38. Volume was 0.2 million shares, significantly below the 3-month average. Gentex has a market cap of $5.1 billion, a P/E ratio of 13.4, and a dividend yield of 2.01%. Recent insider transactions include two sales totaling $273,000 in the last 90 days. No unusual options activity or social media chatter was reported in the past 24 hours.

What To Watch

The stock is currently trading near its 52-week low. Investors may look for further commentary from analysts or additional corporate updates. Gentex’s dividend of $0.12 per share was most recently ex-dividend on July 8, 2026. Coverage breadth and any follow-up from UBS, which maintains a Neutral rating with a $25 price target, could also influence near-term sentiment.